Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1795117 Target Snapshot

Histone-lysine N-methyltransferase, H3 lysine-79 specific · SINGLE PROTEIN · Homo sapiens

446Compounds
199Assays
1Approved Drugs
405.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q8TEK3. Use UniProt Q8TEK3 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q8TEK3 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Histone-lysine N-methyltransferase, H3 lysine-79 specific as ChEMBL target CHEMBL1795117, mapped to UniProt Q8TEK3. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Histone-lysine N-methyltransferase, H3 lysine-79 specific
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1795117
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q8TEK3
Histone-lysine N-methyltransferase, H3 lysine-79 specific
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Histone-lysine N-methyltransferase, H3 lysine-79 specific is the right protein anchor across sources, using UniProt Q8TEK3 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelHistone-lysine N-methyltransferase, H3 lysine-79 specific
UniProt AccessionQ8TEK3
Component TypeProtein
Sequence Length1537 aa

Histone-lysine N-methyltransferase, H3 lysine-79 specific

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Histone-lysine N-methyltransferase, H3 lysine-79 specific, mapped to UniProt Q8TEK3. Sequence length is 1537 aa.

Mapped IDQ8TEK3
Review nameHistone-lysine N-methyltransferase, H3 lysine-79 specific
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

1
Approved
4
Phase II
Assay Mix

Activity Type Distribution

IC50252.0
KI112.0
EC507.0
KD34.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5764114 11.0 Kd 0.01 Preclinical
CHEMBL3414626 10.92 Ki 0.012 Clinical
CHEMBL3087498 10.25 Kd 0.0561 Preclinical
CHEMBL4590355 10.1 Ki 0.08 Preclinical
CHEMBL4446126 9.96 IC50 0.11 Preclinical
CHEMBL4081752 9.82 IC50 0.15 Preclinical
CHEMBL4435508 9.77 IC50 0.17 Preclinical
CHEMBL4567485 9.72 IC50 0.19 Preclinical
CHEMBL2169919 9.6 Kd 0.25 Preclinical
CHEMBL5176983 9.52 IC50 0.3 Preclinical
Distribution

pChEMBL Value Distribution

37
5.0
22
5.5
21
6.0
34
6.5
27
7.0
20
7.5
20
8.0
17
8.5
25
9.0
15
9.5
pChEMBL
Assay Landscape

Assay Landscape

199
Total Assays
226
Tested Compounds
2
Assay Types
Binding — 198 assays, 226 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 126 152 6.8
cell-based format 39 20 6.7
assay format 33 54 6.3
ADME — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine